Bausch Health Companies Investor Conference Presentation Deck
3Q21 Revenue Results
Three Months Ended
BAUSCH + LOMB
Bausch Pharma4
12
Bausch+Lomb ³ Segment
Global Vision Care
Global Surgical
Global Consumer³
Global Ophtho Rx³
Bausch+Lomb Company
Salix Segment
International Rx³
Segment
Ortho Dermatologics ³
Segment
Ortho Dermatologics ³
Global Solta
Diversified Products ³
Segment
Neuro & Other³
Generics ³
Dentistry
Bausch Pharma4
Company ¹,5
Total Bausch Health
Revenues
BAUSCH- Health
9.30.21
$949 M
$226M
$173M
$379M
$171M
$949M
$527M
$271M
$140M
$66M
$74M
$224M
$151M
$48M
$25M
$1,162M
$2,111M
9.30.20
$916M
$214M
$151M
$351M
$200M
$916M
$496M
$308M
$143M
$70M
$73M
$275M
$200M
$56M
$19M
$1,222M
$2,138M
Favorable (Unfavorable)
Organic
Change ¹,2
3%
6%
Reported
4%
6%
15%
8%
(15%)
4%
6%
(12%)
(2%)
(6%)
1%
(19%)
(25%)
(14%)
32%
(5%)
(1%)
13%
7%
(15%)
3%
6%
(1%)
(3%)
(6%)
(1%)
(19%)
(25%)
(14%)
32%
(2%)
0%
Nine Months Ended
9.30.21
$2,764M
$666M
$520M
$1,051 M
$527M
$2,764M
$1,515M
$890M
$418M
$199M
$219M
$651M
$448M
$127M
$76M
$3,474M
$6,238M
9.30.20
$2,468 M
$542M
$394M
$986M
$546M
$2,468M
$1,377M
$848M
$391M
$225M
$166M
$730M
$506M
$176M
$48M
$3,346M
$5,814M
Favorable (Unfavorable)
Organic
Change ¹,2
10%
Reported
12%
23%
32%
7%
(3%)
12%
10%
5%
7%
(12%)
32%
(11%)
(11%)
(28%)
58%
4%
7%
21%
28%
5%
(6%)
10%
10%
6%
5%
(12%)
27%
(10%)
(10%)
(27%)
58%
4%
6%
1. See Slide 2 and Appendix for further non-GAAP information.
2. Organic growth/change, a non-GAAP metric, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations.
3. In connection with the planned separation of the Company's eye health business into an independently traded entity from the remainder of Bausch Health Companies Inc, the Company has realigned and has begun operating in a
manner consistent with the organizational structure of the two separate entities as proposed by the separation. Commencing in Q1 2021, the Company realigned its segment reporting structure and now operates in five reportable
segments. Further in Q2 2021, the Company moved certain products previously reported in the International Rx Business Unit to the Global Consumer or Global Ophtho Rx business units. For more information about the current
segment reporting structure, please see "New Segment Structure" and "New Segment Realignment" appendix slides in this Earnings presentation.
4. The remainder of Bausch Health is referred to as "Bausch Pharma" and will assume a new name upon the separation of the Company's eye health business, Bausch + Lomb.
5. Bausch Pharma revenues, a non-GAAP metric, are determined by subtracting Bausch+Lomb segment revenues for the applicable period from total Bausch Health revenues for the applicable period.View entire presentation